Impact of P53 and SIRT1 in Type 2 Diabetes

Sherief Abd-Elsalam

Status and phase: Enrolling; Phase 3

Conditions: DM

Treatments: Drug: Nigetella salivata; Other: life style; Drug: Metformin

Study type: Interventional

Funder types: Other

Identifiers

NCT03925714

dm 2

Details and patient eligibility

About

Investigating the impact of p53 and SIRT1 in the development of type 2 DM

Full description

Investigating the impact of p53 and SIRT1 in the development of type 2 DM through the treatment of prediabetic individuals by either nigetella salivata or Metformin

Enrollment: 90 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Prediabetic subjects.

Exclusion criteria

• Confirmed diabetes.
• Hepatic or renal impairment.

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

90 participants in 3 patient groups

life style

Other group

Description:

life style control only

Treatment:

Other: life style

Metformin

Active Comparator group

Description:

Metformin 500 mg twice daily

Treatment:

Drug: Metformin

Nigetella salivata

Experimental group

Description:

NS 450 mg twice daily

Treatment:

Drug: Nigetella salivata